Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips This article is excerpted from Tom Yeung’s Moonshot Investor newsletter. To make sure you don’t miss any of Tom’s potential 100x picks, subscribe to his mailing list here . Source: Chad McDermott...
Gainers: ReWalk Robotics (NASDAQ:RWLK) +37%, Ontrak (NASDAQ:OTRK) +35%, Alzamend Neuro (NASDAQ:ALZN) +32%, Chinook Therapeutics (NASDAQ:KDNY) +23%, Alimera Sciences (NASDAQ:ALIM) +22%. Losers: Deciphera Pharmaceuticals (NASDAQ:DCPH) -74%, Cali...
Image source: The Motley Fool. Alimera Sciences, inc (NASDAQ: ALIM) Q3 2021 Earnings Call Oct 28, 2021 , 9:00 a.m. ET Operator Continue reading For further details see: Alimera Sciences, inc (ALIM) Q3 2021 Earnings Call Transcript
Alimera Sciences, Inc. (ALIM) Q3 2021 Earnings Conference Call October 28, 2021, 09:00 ET Company Participants Scott Gordon - CORE IR Richard Eiswirth - President, CEO & Director Philip Jones - CFO Conference Call Participants Alexander Nowak - Craig-Hallum Yi Chen - H.C. Wainwright &...
Alimera Sciences (NASDAQ:ALIM): Q3 GAAP EPS of -$0.60 misses by $0.07. Revenue of $12.15M (-2.6% Y/Y) misses by $0.22M. Press Release For further details see: Alimera Sciences EPS misses by $0.07, misses on revenue
Consolidated Net Revenue of $12.2 Million Down 2% vs. Third Quarter of 2020 and Up 14% vs. Second Quarter of 2021 U.S. End User Demand up 15% vs. Third Quarter of 2020 and Second Quarter of 2021 ATLANTA, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences,...
AB, ABEV, ABMD, ADS, AEP, AGCO, ALDX, ALIM, ALNY, AMT, AOS, ARGX, ASX, OTCPK:ATGFF, ATI, AVNT, BAX, BC, OTCQX:BDRBF, BPMC, BTU, BUD, CARR, CAT, CBRE, CFR, CG, CHKP, CMCSA, CMS, CNSL, CNX, COHU, COOP, COR, CPG, CRS, CVEO, CWT, CX, OTCPK:DASTY, DBD, DQ, OTCPK:EADSF, EXP, FLWS, GNCA, GPI, GTX, G...
ATLANTA, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera) a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and to maintain better vision longer, announces today that it will ...
Gainers: Jasper Therapeutics JSPR +114%, Clarus Therapeutics (NASDAQ:CRXT) +45%, Alimera Sciences ALIM +19%, Revance Therapeutics RVNC +13%, Recursion Pharmaceuticals (NASDAQ:RXRX) +12%. Losers: NeuroOne Medical Technologies NMTC -25%, Ne...
PALADIN Study Data Presented at the American Society of Retina Specialists Shows That Post-ILUVIEN, the Percentage of Eyes Receiving One Yearly Treatment or Less Increased 3.2-Fold Compared to Pre-ILUVIEN ATLANTA, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALI...
News, Short Squeeze, Breakout and More Instantly...
Alimera Sciences Inc. Company Name:
ALIM Stock Symbol:
NASDAQ Market:
Alimera Sciences Inc. Website:
2024-07-07 16:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-25 11:30:02 ET Alliance Global Partners analyst issues NEUTRAL recommendation for ALIM on June 25, 2024 10:23AM ET. The previous analyst recommendation was Buy. ALIM was trading at $5.53 at issue of the analyst recommendation. The overall analyst consensus : HOLD...
2024-06-25 07:00:05 ET Yi Chen from H.C. Wainwright issued a price target of $6.00 for ALIM on 2024-06-25 06:08:00. The adjusted price target was set to $6.00. At the time of the announcement, ALIM was trading at $5.54. The overall price target consensus is at $7.25 with...